BioSpace News Archive

The Cystic Fibrosis Foundation will invest up to $15 million in ReCode Therapeutics for the development of its messenger RNA (mRNA) therapy that could eventually provide a treatment option for all people with cystic fibrosis regardless of their mutations.

Twist Bioscience Corporation and Centogene N.V. today announced the launch of three next-generation sequencing (NGS) target enrichment panels to support rare disease and hereditary cancer research and support diagnostics.

Nascent Biotech, Inc. announced today the completion and closure of enrollment for the final cohort of patients involved in the Company’s Phase I trial to evaluate Pritumumab as a treatment for Brain Cancer.

Noven Pharmaceuticals. Inc., (Noven) announced today that XELSTRYM™ (dextroamphetamine) transdermal system, CII, the first and only FDA-approved amphetamine patch for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients six years and older, will be available across the U.S. for healthcare professionals to prescribe later in the first quarter of 2023.

SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions.

Sysmex America, Inc. announced that Chris Cappella has joined the Company as Chief Financial Officer.

Vivalink, a leading provider of digital healthcare solutions, announces its biometric data platform has been successfully integrated into Elevate Addiction Services’ drug and alcohol in-patient detox treatment program.

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.

Cerveau Technologies, Inc. today announced a research collaboration agreement with Othair Prothena Limited, a subsidiary of Prothena Corporation plc (Prothena), which will enable Prothena to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.

Prevencio, Inc., The AI-Powered Cardiac Blood Test Company, announced the Centers for Medicare & Medicaid Services has set a National Medicare payment rate of $390.75 for each of the Company’s three lead proprietary HART® cardiac blood tests.